BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19262599)

  • 21. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
    Gotlib J; Akin C
    Semin Hematol; 2012 Apr; 49(2):128-37. PubMed ID: 22449623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced DNA methylation and hydroxymethylation in patients with systemic mastocytosis.
    Leoni C; Montagner S; Deho' L; D'Antuono R; De Matteis G; Marzano AV; Merante S; Orlandi EM; Zanotti R; Monticelli S
    Eur J Haematol; 2015 Dec; 95(6):566-75. PubMed ID: 25688802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive mutational profiling in advanced systemic mastocytosis.
    Schwaab J; Schnittger S; Sotlar K; Walz C; Fabarius A; Pfirrmann M; Kohlmann A; Grossmann V; Meggendorfer M; Horny HP; Valent P; Jawhar M; Teichmann M; Metzgeroth G; Erben P; Ernst T; Hochhaus A; Haferlach T; Hofmann WK; Cross NC; Reiter A
    Blood; 2013 Oct; 122(14):2460-6. PubMed ID: 23958953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.
    Gorantla SP; Zirlik K; Reiter A; Yu C; Illert AL; Von Bubnoff N; Duyster J
    Leukemia; 2015 Aug; 29(8):1763-70. PubMed ID: 25761934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
    Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
    Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
    Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, genetic, and therapeutic insights into systemic mast cell disease.
    Tefferi A; Pardanani A
    Curr Opin Hematol; 2004 Jan; 11(1):58-64. PubMed ID: 14676628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
    Lierman E; Smits S; Cools J; Dewaele B; Debiec-Rychter M; Vandenberghe P
    Leukemia; 2012 Jul; 26(7):1693-5. PubMed ID: 22301675
    [No Abstract]   [Full Text] [Related]  

  • 35. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
    Tefferi A
    J Cell Mol Med; 2009 Feb; 13(2):215-37. PubMed ID: 19175693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
    Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
    Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
    Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
    Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
    [No Abstract]   [Full Text] [Related]  

  • 38. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
    Tefferi A; Pardanani A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Gangat N; Finke CM; Schwager S; Mullally A; Li CY; Hanson CA; Mesa R; Bernard O; Delhommeau F; Vainchenker W; Gilliland DG; Levine RL
    Leukemia; 2009 May; 23(5):905-11. PubMed ID: 19262601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
    Gotlib J; Gerds AT; Bose P; Castells MC; Deininger MW; Gojo I; Gundabolu K; Hobbs G; Jamieson C; McMahon B; Mohan SR; Oehler V; Oh S; Padron E; Pancari P; Papadantonakis N; Pardanani A; Podoltsev N; Rampal R; Ranheim E; Rein L; Snyder DS; Stein BL; Talpaz M; Thota S; Wadleigh M; Walsh K; Bergman MA; Sundar H
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1500-1537. PubMed ID: 30545997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
    Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
    Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.